Lnp-Targeting Hematopoietic Stem Cells and Lentiviral Gene Transfer to Generate and Rescue a Novel Mouse Model of Lethal Alpha-Thalassemia
Maxwell Chappell(Children's Hospital of Philadelphia), Stefano Rivella(Children's Hospital of Philadelphia), Danuta Jarocha(Jagiellonian University), Amaliris Guerra(Children's Hospital of Philadelphia), Stavros Glentis, Valentina Ghiaccio(Children's Hospital of Philadelphia), Antonis Kattamis, Michael Triebwasser(University of Michigan), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Laura Breda(Children's Hospital of Philadelphia), Hamideh Parhiz(Translational Therapeutics (United States)), Kandace Gollomp(Children's Hospital of Philadelphia), Megan Fedorky(Children's Hospital of Philadelphia), Nattiya Teawtrakul(Khon Kaen University), Tyler E. Papp(Translational Therapeutics (United States))
Cited by 0
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
|Molecular Therapy|2021|272
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244